domperidone
domperidone .JPG

domperidone

CLINICAL USE

Anti-emetic:Cancer chemotherapy Postoperative nausea and vomiting (PONV)

DOSE IN NORMAL RENAL FUNCTION

Chemotherapy: IV bolus or infusion: 100 mg —30 minutes before chemotherapyOral: 200 mg 1 hour before —chemotherapy, then 200 mg daily to prevent delayed nausea and vomitingPONV: IV bolus or infusion: 12.5 mg —Oral: 50 mg before induction of —anaesthesia

PHARMACOKINETICS

  • Molecular weight                           :420.5
  • %Protein binding                           :69–77
  • %Excreted unchanged in urine     : 50–60
  • Volume of distribution (L/kg)       :5–7.9
  • half-life – normal/ESRD (hrs)      :7–9/Increased

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unknown dialysability. Dose as in normal renal function
  • HD                     :Unknown dialysability. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsAnti-arrhythmics: increased risk of ventricular arrhythmias – avoid concomitant useBeta-blockers: increased risk of ventricular arrhythmias with sotalol – avoid concomitant use

    ADMINISTRATION

    Reconstition

    Route

    Oral, IV bolus,

    IV infusion

    Rate of Administration

    Bolus: over 30 seconds Infusion: over 15 minutes

    Comments

    Can be added to 50 mL sodium chloride 0.9%, glucose 5% or compound sodium lactate

    OTHER INFORMATION

    Peak concentrations occur 1 hour after oral and 0.6 hour after IV dosesOral bioavailability of 75% Active metabolite is renally excreted (approximately 30%)In patients with severe renal impairment (creatinine clearance
  • <10           : mL/min), maximum plasma levels of metabolite are increased 17% or 34%, respectively, after intravenous or oral administration of dolasetron, and systemic exposure is increased approximately 2-fold dolasetron mesilate.



    See how to identify renal failure stages according to GFR calculation

    See how to diagnose irreversible renal disease

    Home

  • other drugs